{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:10:08Z","timestamp":1782393008471,"version":"3.54.5"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11897-020-00453-3","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T11:03:10Z","timestamp":1583233390000},"page":"43-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Personalized Approach to Cancer Treatment\u2013Related Cardiomyopathy"],"prefix":"10.1007","volume":"17","author":[{"given":"Jeremy","family":"Slivnick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Vallakati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"453_CR1","unstructured":"Reboux G. Cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer. September 12, 2018. Accessed November 11, 2019."},{"issue":"2","key":"453_CR2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1200\/JOP.2015.003772","volume":"11","author":"American Society of Clinical Oncology","year":"2015","unstructured":"American Society of Clinical Oncology. The state of cancer care in America, 2015: a report by the American Society of Clinical Oncology. Journal of Oncology Practice. 2015;11(2):79\u2013113.","journal-title":"Journal of Oncology Practice"},{"issue":"3","key":"453_CR3","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","volume":"13","author":"JL Patnaik","year":"2011","unstructured":"Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Research BCR. 2011;13(3):R64.","journal-title":"Breast Cancer Research BCR"},{"issue":"2","key":"453_CR4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","volume":"32","author":"EA Lefrak","year":"1973","unstructured":"Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302\u201314.","journal-title":"Cancer"},{"issue":"20","key":"453_CR5","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","volume":"70","author":"H-M Chang","year":"2017","unstructured":"\u2022 Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. Journal of the American College of Cardiology. 2017;70(20):2536\u201351. This paper discusses about the best practice guidelines for management of cancer-therapy mediated cardiomyopathy.","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"453_CR6","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Medicine. 2012;18(11):1639\u201342.","journal-title":"Nature Medicine"},{"key":"453_CR7","volume-title":"Cardio-oncology. Braunwald\u2019s heart disease: a textbook of cardiovascular medicine","author":"B Ky","year":"2015","unstructured":"Ky B. In: Zypes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E, editors. Cardio-oncology. Braunwald\u2019s heart disease: a textbook of cardiovascular medicine. Philadelphia: Elsevier; 2015."},{"issue":"5","key":"453_CR8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","volume":"131","author":"KA Wouters","year":"2005","unstructured":"Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology. 2005;131(5):561\u201378.","journal-title":"British Journal of Haematology"},{"issue":"22","key":"453_CR9","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981\u20138.","journal-title":"Circulation"},{"issue":"11","key":"453_CR10","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869\u201379.","journal-title":"Cancer"},{"issue":"4","key":"453_CR11","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1200\/JOP.2016.018770","volume":"13","author":"SH Armenian","year":"2017","unstructured":"\u2022 Armenian SH, Lacchetti C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary. Journal of Oncology Practice. 2017;13(4):270\u20135. This paper is a consensus document which discusses the role of close monitoring and surveillance in cancer survivors.","journal-title":"Journal of Oncology Practice"},{"issue":"2","key":"453_CR12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11764-014-0408-9","volume":"9","author":"A Qin","year":"2015","unstructured":"Qin A, Thompson CL, Silverman P. Predictors of late-onset heart failure in breast cancer patients treated with doxorubicin. Journal of Cancer Survivorship: Research and Practice. 2015;9(2):252\u20139.","journal-title":"Journal of Cancer Survivorship: Research and Practice"},{"issue":"23","key":"453_CR13","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","volume":"65","author":"GT Armstrong","year":"2015","unstructured":"Armstrong GT, Joshi VM, Ness KK, Marwick TH, Zhang N, Srivastava DK, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. Journal of the American College of Cardiology. 2015;65(23):2511\u201322.","journal-title":"Journal of the American College of Cardiology"},{"issue":"9","key":"453_CR14","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. Journal of the American College of Cardiology. 2014;64(9):938\u201345.","journal-title":"Journal of the American College of Cardiology"},{"key":"453_CR15","doi-asserted-by":"crossref","unstructured":"Armenian, Saro, and Smita Bhatia. Predicting and preventing anthracycline-related cardiotoxicity. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting 38 (2018): 3\u201312.","DOI":"10.1200\/EDBK_100015"},{"issue":"11","key":"453_CR16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine. March 15, 2001;344(11):783\u201392.","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"453_CR17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","volume":"106","author":"D Keulenaer","year":"2010","unstructured":"Keulenaer D, Gilles W, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circulation Research. 2010;106(1):35\u201346.","journal-title":"Circulation Research"},{"issue":"1","key":"453_CR18","doi-asserted-by":"crossref","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","volume":"9","author":"MW Bloom","year":"2016","unstructured":"\u2022\u2022 Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circulation. Heart Failure. 2016;9(1):e002661. This paper provides comprehensive review of cancer therapy-related cardiomyopathy enumerating the etiology, risk factors, and screening modalities.","journal-title":"Circulation. Heart Failure"},{"issue":"21","key":"453_CR19","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","volume":"28","author":"M Procter","year":"2010","unstructured":"Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(21):3422\u20138.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"6","key":"453_CR20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","volume":"34","author":"PP Advani","year":"2016","unstructured":"Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. February 20, 2016;34(6):581\u20137.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"17","key":"453_CR21","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJ Bowles","year":"2012","unstructured":"Bowles EJ, Aiello RW, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. Journal of the National Cancer Institute. 2012;104(17):1293\u2013305.","journal-title":"Journal of the National Cancer Institute"},{"issue":"24","key":"453_CR22","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. Journal of the American College of Cardiology. 2012;60(24):2504\u201312.","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"453_CR23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2004;22(2):322\u20139.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5502","key":"453_CR24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (New York, N.Y.). 2001;291(5502):319\u201322.","journal-title":"Science (New York, N.Y.)"},{"issue":"21","key":"453_CR25","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085\u20137.","journal-title":"Circulation"},{"issue":"18","key":"453_CR26","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. The New England Journal of Medicine. 2016;375(18):1749\u201355.","journal-title":"The New England Journal of Medicine"},{"issue":"16","key":"453_CR27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. Journal of the American College of Cardiology. 2018;71(16):1755\u201364.","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"453_CR28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2019.07.006","volume":"74","author":"MY Desai","year":"2019","unstructured":"Desai MY, Windecker S, Lancellotti P, Bax JJ, Griffin BP, Cahlon O, et al. Prevention, diagnosis, and management of radiation-associated cardiac disease: JACC Scientific Expert Panel. Journal of the American College of Cardiology. 2019;74(7):905\u201327.","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"453_CR29","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Petersen EJ, Raemaekers JMM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Internal Medicine. 2015;175(6):1007\u201317.","journal-title":"JAMA Internal Medicine"},{"issue":"11","key":"453_CR30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Br\u00f8nnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. The New England Journal of Medicine. March 14, 2013;368(11):987\u201398.","journal-title":"The New England Journal of Medicine"},{"issue":"15","key":"453_CR31","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","volume":"135","author":"H Saiki","year":"2017","unstructured":"Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, et al. Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. April 11, 2017;135(15):1388\u201396.","journal-title":"Circulation"},{"issue":"16","key":"453_CR32","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","volume":"129","author":"FA van Nimwegen","year":"2017","unstructured":"van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257\u201365.","journal-title":"Blood"},{"issue":"8","key":"453_CR33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","volume":"6","author":"SC Darby","year":"2005","unstructured":"Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. The Lancet. Oncology. August 2005;6(8):557\u201365.","journal-title":"The Lancet. Oncology"},{"issue":"9","key":"453_CR34","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.echo.2013.07.005","volume":"26","author":"L Patrizio","year":"2013","unstructured":"Patrizio L, Nkomo VT, Badano LP, Bergler-Klein J, Bergler J, Bogaert J, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2013;26(9):1013\u201332.","journal-title":"Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography"},{"issue":"13","key":"453_CR35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","volume":"35","author":"RT Dess","year":"2017","unstructured":"Dess RT, Sun Y, Matuszak MM, Sun G, Soni PD, Bazzi L, et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017;35(13):1395\u2013402.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5","key":"453_CR36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","volume":"68","author":"MA Goldberg","year":"1986","unstructured":"Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68(5):1114\u20138.","journal-title":"Blood"},{"issue":"5","key":"453_CR37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1532\/IJH97.E0620","volume":"85","author":"S Zver","year":"2007","unstructured":"Zver S, Zadnik V, Bunc M, Rogel P, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. International Journal of Hematology. 2007;85(5):408\u201314.","journal-title":"International Journal of Hematology"},{"issue":"11","key":"453_CR38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):61\u20131753.","journal-title":"Haematologica"},{"key":"453_CR39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ethier J-L, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treatment Reviews. 2017;53:120\u20137.","journal-title":"Cancer Treatment Reviews"},{"issue":"9604","key":"453_CR40","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet (London, England). 2007;370(9604):2011\u20139.","journal-title":"Lancet (London, England)"},{"issue":"9","key":"453_CR41","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","volume":"20","author":"G Di Lorenzo","year":"2009","unstructured":"Di Lorenzo G, Autorino R, Bruni G, Carten\u00ec G, Ricevuto E, Tudini M, et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Annals of Oncology: Official Journal of the European Society for Medical Oncology. September 2009;20(9):1535\u201342.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"1","key":"453_CR42","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","volume":"3","author":"G Ezaz","year":"2014","unstructured":"Ezaz G, Long JB, Gross CP, Chen J. Risk Prediction Model for Heart Failure and Cardiomyopathy after Adjuvant Trastuzumab Therapy for Breast Cancer. Journal of the American Heart Association. 2014;3(1):e000472.","journal-title":"Journal of the American Heart Association"},{"issue":"3","key":"453_CR43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-007-9803-5","volume":"107","author":"G Dranitsaris","year":"2008","unstructured":"Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Research and Treatment. 2008;107(3):443\u201350.","journal-title":"Breast Cancer Research and Treatment"},{"key":"453_CR44","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Journal of Cardiac Failure. et al., 2017;23(8):628\u201351."},{"issue":"16","key":"453_CR45","doi-asserted-by":"crossref","first-page":"e147-239","DOI":"10.1016\/j.jacc.2013.05.020","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology. 2013;62(16):e147-239.","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"453_CR46","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging. 2014;15(10):1063\u201393.","journal-title":"European Heart Journal Cardiovascular Imaging"},{"issue":"1","key":"453_CR47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","volume":"61","author":"P Thavendiranathan","year":"2013","unstructured":"Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovi\u0107 ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. Journal of the American College of Cardiology. 2013;61(1):77\u201384.","journal-title":"Journal of the American College of Cardiology"},{"issue":"25 Pt A","key":"453_CR48","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","volume":"63","author":"P Thavendiranathan","year":"2014","unstructured":"Thavendiranathan P, Poulin F, Lim K-D, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. Journal of the American College of Cardiology. 2014;63(25 Pt A):2751\u201368.","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"453_CR49","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","volume":"5","author":"H Sawaya","year":"2012","unstructured":"Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circulation. Cardiovascular Imaging. 2012;5(5):596\u2013603.","journal-title":"Circulation. Cardiovascular Imaging"},{"issue":"8","key":"453_CR50","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jcmg.2018.03.019","volume":"11","author":"T Negishi","year":"2018","unstructured":"Negishi T. Paaladinesh Thavendiranathan, Kazuaki Negishi, Thomas H. Marwick, and SUCCOUR investigators. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR Trial. JACC. Cardiovascular Imaging. 2018;11(8):1098\u2013105.","journal-title":"JACC. Cardiovascular Imaging"},{"issue":"9 Supplement 1","key":"453_CR51","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0735-1097(19)31283-5","volume":"73","author":"L Zhang","year":"2019","unstructured":"Zhang L, Awadalla M, Mahmood SS, Groarke JD, Nohria A, Liu S, et al. Late gadolinium enhancement in patients with myocarditis from immune checkpoint inhibitors. Journal of the American College of Cardiology. 2019;73(9 Supplement 1):675.","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"453_CR52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","volume":"36","author":"D Cardinale","year":"2000","unstructured":"Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. Journal of the American College of Cardiology. 2000;36(2):517\u201322.","journal-title":"Journal of the American College of Cardiology"},{"issue":"22","key":"453_CR53","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749\u201354.","journal-title":"Circulation"},{"issue":"25","key":"453_CR54","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(25):3910\u20136.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"11","key":"453_CR55","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2011.439","volume":"105","author":"S Romano","year":"2011","unstructured":"Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, et al. Serial measurements of NT-ProBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. British Journal of Cancer. 2011;105(11):1663\u20138.","journal-title":"British Journal of Cancer"},{"issue":"8","key":"453_CR56","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1373\/clinchem.2005.050153","volume":"51","author":"MT Sandri","year":"2005","unstructured":"Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clinical Chemistry. 2005;51(8):1405\u201310.","journal-title":"Clinical Chemistry"},{"key":"453_CR57","unstructured":"FDA Drug Label for HERCEPTIN- trastuzumab. Available at: http:\/\/ dailymed.nlm.nih.gov.ezproxy.hsclib.sunysb.edu\/dailymed\/drugInfo. cfm?setid\u2009=\u2009492dbdb2-077e-4064-bff3-372d6af0a7a2%3E."},{"issue":"17","key":"453_CR58","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2018;36(17):1714\u201368.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"Suppl 7","key":"453_CR59","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2012;23(Suppl 7):vii155\u201366.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"3","key":"453_CR60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.1984.2.3.207","volume":"2","author":"M Valdivieso","year":"1984","unstructured":"Valdivieso M, Burgess MA, Ewer MS, Mackay B, Wallace S, Benjamin RS, et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1984;2(3):207\u201314.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"453_CR61","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1997.15.4.1318","volume":"15","author":"SM Swain","year":"1997","unstructured":"Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1997;15(4):1318\u201332.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"4","key":"453_CR62","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","volume":"17","author":"M Marty","year":"2006","unstructured":"Marty M, Espi\u00e9 M, Llombart A, Monnier A, Rapoport BL, Stahalova V, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2006;17(4):614\u201322.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"5","key":"453_CR63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1200\/JCO.2005.02.3879","volume":"25","author":"CK Tebbi","year":"2007","unstructured":"Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia\/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin\u2019s disease. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2007;25(5):493\u2013500.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"31","key":"453_CR64","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Vooletich MT, Durand J-B, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(31):7820\u20136.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"10","key":"453_CR65","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1634\/theoncologist.2015-0125","volume":"20","author":"AF Yu","year":"2015","unstructured":"Yu AF, Yadav NU, Eaton AA, Lung BY, Thaler HT, Liu JE, et al. Continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. The Oncologist. 2015;20(10):1105\u201310.","journal-title":"The Oncologist"},{"issue":"3","key":"453_CR66","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"F Lynce","year":"2019","unstructured":"Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Research and Treatment. 2019;175(3):595\u2013603.","journal-title":"Breast Cancer Research and Treatment"},{"issue":"7","key":"453_CR67","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ctrv.2009.06.007","volume":"35","author":"H Azim","year":"2009","unstructured":"Azim H, Azim HA, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treatment Reviews. 2009;35(7):633\u20138.","journal-title":"Cancer Treatment Reviews"},{"issue":"3","key":"453_CR68","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdr294","volume":"23","author":"D Lenihan","year":"2012","unstructured":"Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2012;23(3):791\u2013800.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"issue":"5","key":"453_CR69","doi-asserted-by":"crossref","first-page":"e819","DOI":"10.1016\/j.clbc.2018.05.010","volume":"18","author":"L Drost","year":"2018","unstructured":"Drost L, Yee C, Lam H, Zhang L, Wronski M, McCann C, et al. A systematic review of heart dose in breast radiotherapy. Clinical Breast Cancer. 2018;18(5):e819\u201324.","journal-title":"Clinical Breast Cancer"},{"issue":"9","key":"453_CR70","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","volume":"58","author":"Zeydin Acar","year":"2011","unstructured":"Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S. Murat Meri\u00e7, and Mustafa Tar\u0131k A\u011fa\u00e7. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. Journal of the American College of Cardiology. 2011;58(9):988\u20139.","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"453_CR71","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","volume":"48","author":"Nihat Kalay","year":"2006","unstructured":"Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A. Tugrul Inanc, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. Journal of the American College of Cardiology. 2006;48(11):2258\u201362.","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"453_CR72","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","volume":"144","author":"R Jhorawat","year":"2016","unstructured":"Jhorawat R, Kumari S, Varma SC, Rohit MK, Narula N, Suri V, et al. Preventive role of carvedilol in adriamycin-induced cardiomyopathy. The Indian Journal of Medical Research. 2016;144(5):725\u20139.","journal-title":"The Indian Journal of Medical Research"},{"issue":"5","key":"453_CR73","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","volume":"69","author":"M Nabati","year":"2017","unstructured":"Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-Induced Cardiotoxicity. Journal of Cardiovascular Pharmacology. 2017;69(5):279\u201385.","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"2","key":"453_CR74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15420\/ahhj.2011.9.2.95","volume":"9","author":"R Salehi","year":"2011","unstructured":"Salehi R, Zamani B, Esfehani A, Ghafari S, Abasnezhad M, Goldust M. Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma. The American Heart Hospital Journal. 2011;9(2):95\u20138.","journal-title":"The American Heart Hospital Journal"},{"issue":"11","key":"453_CR75","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. American Journal of Hematology. 2010;85(11):894\u20136.","journal-title":"American Journal of Hematology"},{"issue":"20","key":"453_CR76","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, Brand\u00e3o SMG, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. Journal of the American College of Cardiology. 2018;71(20):2281\u201390.","journal-title":"Journal of the American College of Cardiology"},{"issue":"21","key":"453_CR77","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. European Heart Journal. 2016;37(21):1671\u201380.","journal-title":"European Heart Journal"},{"issue":"23","key":"453_CR78","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Dom\u00e8nech A, Ortiz-P\u00e9rez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME Trial (PreventiOn of Left Ventricular Dysfunction with Enalapril and CaRvedilol in Patients Submitted to Intensive ChemOtherapy for the Treatment of Malignant HEmopathies). Journal of the American College of Cardiology. 2013;61(23):2355\u201362.","journal-title":"Journal of the American College of Cardiology"},{"issue":"8","key":"453_CR79","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Gietema JA, Kerklaan BM, van Werkhoven ED, Altena R, Honkoop A, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncology. 2016;2(8):1030\u20137.","journal-title":"JAMA Oncology"},{"issue":"8","key":"453_CR80","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2017;35(8):870\u20137.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"23","key":"453_CR81","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474\u201381.","journal-title":"Circulation"},{"issue":"3","key":"453_CR82","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology. 2010;55(3):213\u201320.","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"453_CR83","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England Journal of Medicine. 2014;371(11):993\u20131004.","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"453_CR84","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.amjcard.2009.10.024","volume":"105","author":"J Rickard","year":"2010","unstructured":"Rickard J, Kumbhani DJ, Baranowski B, Martin DO, Tang WH, Wilkoff BL. Usefulness of cardiac resynchronization therapy in patients with adriamycin-induced cardiomyopathy. The American Journal of Cardiology. 2010;105(4):522\u20136.","journal-title":"The American Journal of Cardiology"},{"issue":"8","key":"453_CR85","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.healun.2012.03.018","volume":"31","author":"GH Oliveira","year":"2012","unstructured":"Oliveira GH, Hardaway BW, Kucheryavaya AY, Stehlik J, Edwards LB, Taylor DO. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation. 2012;31(8):805\u201310.","journal-title":"The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation"},{"issue":"3","key":"453_CR86","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jacc.2013.09.040","volume":"63","author":"Guilherme H. Oliveira","year":"2014","unstructured":"Oliveira, Guilherme H., Matthias Dupont, David Naftel, Susan L. Myers, Ya Yuan, W. H. Wilson Tang, Gonzalo Gonzalez-Stawinski, James B. Young, David O. Taylor, and Randall C. Starling. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). Journal of the American College of Cardiology 63, no. 3 (2014): 240\u201348.","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"453_CR87","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/ejechocard\/jer142","volume":"12","author":"A Tanindi","year":"2011","unstructured":"Tanindi A, Demirci U, Tacoy G, Buyukberber S, Alsancak Y, Coskun U, et al. Assessment of right ventricular functions during cancer chemotherapy. European Journal of Echocardiography: The Journal of the Working Group on Echocardiography of the European Society of Cardiology. 2011;12(11):834\u201340.","journal-title":"European Journal of Echocardiography: The Journal of the Working Group on Echocardiography of the European Society of Cardiology"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-020-00453-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11897-020-00453-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-020-00453-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:47:47Z","timestamp":1614732467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11897-020-00453-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1007\/s11897-020-00453-3","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"3 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}